Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Sirolimus-eluting stent may reduce re-blockage in complex coronary lesions, study shows
February 27th, 2006
The Cypher sirolimus-eluting coronary stent may reduce re-blockage (restenosis) and the occurrence of major adverse cardiac events in patients with complex coronary artery lesions without increasing the risk of blood clots (thrombosis), according to a new study published in the Journal of the American College of Cardiology (JACC). The SCANDSTENT study (Stenting of Coronary Arteries in Non-Stress/Benestent Disease) is the only randomized study examining the Cypher stent against bare metal stents that includes complex patients, defined as patients with blockages longer than 15 millimeters, side-branch lesions, ostial lesions, and lesions angled at greater than 45...
Source: Pharma Business Week (2006-02-27)
|
